Skip to main content

Redmile Group, LLC

SEC CIK
0001425738
Latest filing
Aug 14, 2026

Holdings in Q2 2026

Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.

Institution overview
Positions
39
+4 vs. Q1 2026
Portfolio value
$1.49B
−$20.6M (−1.4%) vs. Q1 2026
Filed
Aug 14, 2026
SEC
Holdings of Redmile Group, LLC in Q2 2026
SecurityClassSharesValue% of portfolioShare changeActionHistory
SRRKScholar Rock Holding CorpCOM4,311,092$237.1M15.9%−4,755,529−52.5%ReducedHistory
KRYSKrystal Biotech, Inc.COM632,005$234.9M15.8%−41,500−6.2%ReducedHistory
STOKStoke Therapeutics, Inc.COM3,945,920$129.1M8.7%−218,200−5.2%ReducedHistory
IMNMImmunome Inc.COM4,911,590$104.1M7.0%−647,295−11.6%ReducedHistory
NRIXNurix Therapeutics, Inc.COM4,073,787$98.8M6.6%−3,659,021−47.3%ReducedHistory
ABSIAbsci CorpCOM6,739,675$78.1M5.2%−1,513,641−18.3%ReducedHistory
ANNXAnnexon, Inc.COM11,869,877$67.8M4.6%−2,679,891−18.4%ReducedHistory
RGNXREGENXBIO Inc.COM4,368,804$52.3M3.5%00.0%UnchangedHistory
STTKShattuck Labs, Inc.COM6,892,033$47.8M3.2%+1,352,309+24.4%AddedHistory
NGNENeurogene Inc.COM1,412,199$44.4M3.0%−47,400−3.2%ReducedHistory
BEAMBeam Therapeutics Inc.COM1,164,259$40.0M2.7%−73,400−5.9%ReducedHistory
AGMBAgomAb Therapeutics NVSPONSORED ADS2,733,926$35.5M2.4%+2,577,676+1,649.7%AddedHistory
FATEFate Therapeutics IncCOM12,872,946$34.8M2.3%00.0%UnchangedHistory
IDYAIDEAYA Biosciences, Inc.COM640,202$23.9M1.6%+119,085+22.9%AddedHistory
SLNSilence Therapeutics plcADS2,164,777$23.8M1.6%00.0%UnchangedHistory
COGTCogent Biosciences, Inc.COM503,321$19.5M1.3%−184,715−26.8%ReducedHistory
SLDBSolid Biosciences Inc.COM NEW1,948,695$19.5M1.3%−63,200−3.1%ReducedHistory
NUVBNuvation Bio Inc.COM CL A3,031,009$17.2M1.2%−122,247−3.9%ReducedHistory
CLDXCelldex Therapeutics, Inc.COM NEW433,921$16.1M1.1%+172,413+65.9%AddedHistory
CLYMClimb Bio, Inc.COM1,226,330$16.0M1.1%+1,226,330NewHistory
ALXOAlx Oncology Holdings IncCOM7,392,504$15.3M1.0%−571,684−7.2%ReducedHistory
BMRNBiomarin Pharmaceutical IncCOM265,169$15.2M1.0%+91,310+52.5%AddedHistory
XENEXenon Pharmaceuticals Inc.COM229,374$13.8M0.9%−33,300−12.7%ReducedHistory
ZYMEZymeworks Inc.COM491,654$12.9M0.9%00.0%UnchangedHistory
ADCTADC Therapeutics SASHS11,526,710$12.3M0.8%−3,943,792−25.5%ReducedHistory
AURAAura Biosciences, Inc.COM1,666,667$11.8M0.8%+1,666,667NewHistory
ODTXOdyssey Therapeutics, Inc.COMMON STOCK425,000$7.95M0.5%+425,000NewHistory
LIVNLivaNova PLCSHS93,154$7.66M0.5%−15,200−14.0%ReducedHistory
ESTAEstablishment Labs Holdings Inc.COM88,964$7.63M0.5%−14,500−14.0%ReducedHistory
CBLLCeribell, Inc.COM386,786$7.52M0.5%00.0%UnchangedHistory
DBVTDBV Technologies S.A.SPONSORED ADS410,440$6.73M0.5%−80,900−16.5%ReducedHistory
INSMINSMED IncCOM PAR $.0151,234$5.46M0.4%+51,234NewHistory
PRMEPrime Medicine, Inc.COM1,389,632$5.13M0.3%−201,200−12.6%ReducedHistory
ATRAAtara Biotherapeutics, Inc.COM NEW441,701$5.07M0.3%00.0%UnchangedHistory
EPRXEupraxia Pharmaceuticals Inc.COM611,400$4.04M0.3%−88,600−12.7%ReducedHistory
ORICOric Pharmaceuticals, Inc.COM362,010$3.92M0.3%−53,700−12.9%ReducedHistory
ARDXArdelyx, Inc.COM641,750$3.27M0.2%−91,600−12.5%ReducedHistory
IVVDInvivyd, Inc.COM2,597,759$2.27M0.2%−50,900−1.9%ReducedHistory
PLRXPliant Therapeutics, Inc.COM772,126$880.2K0.1%00.0%UnchangedHistory